Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7861194 | 0.84 | PTGS2 (0.41) | PPARAPPARGCA12CA1CA2 | |
| SCHEMBL7208021 | 0.83 | PPARA (0.42) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL7853435 | 0.81 | PPARA (0.39) | PPARAPPARGCA1CA2CA7 | |
| SCHEMBL7211561 | 0.81 | CACNA1F (0.46) | KDM4E | |
| SCHEMBL7858920 | 0.80 | PPARA (0.53) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6053157 | 0.78 | L3MBTL1 (0.39) | PPARGCA12CA1CA2CA9 | |
| SCHEMBL7860273 | 0.77 | ESR1 (0.39) | CA2KDM4EADORA3SIGMAR1 | |
| SCHEMBL7858929 | 0.75 | SLC6A4 (0.36) | — | |
| SCHEMBL2686642 | 0.75 | PPARA (0.52) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL13156122 | 0.73 | PPARA (0.57) | PPARAPPARGPPARDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515984-B1 | PEPTIDE DERIVATIVES COMPRISING THIAZEPINE GROUP FOR THE TREATMENT OF HYPERLIPIDEMIC CONDITIONS | ALBIREO AB (SE) | 2009-03-04 | — | — | EP | claimed |
| WO-2007093747-A2 | USE OF TESAGLITIZAR FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-08-23 | — | — | WO | claimed |
| WO-2007093747-A2 | USE OF TESAGLITIZAR FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-08-23 | — | — | WO | disclosed |
| EP-1404309-B1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL| PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY| PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1404309-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1401485-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY)PHENYL] PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1399166-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | AstraZeneca AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1237855-B1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1237854-B1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6531622-B1 | Insulin Resistance Syndrome; metabolic disorders; crystallization | ASTRAZENECA AB (SE) | 2003-03-11 | — | — | US | disclosed |
| EP-1237854-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1084103-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062872-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |